# Lutein-based dye vitrectomy for idiopathic epiretinal membrane: a pilot study

**Authors:** Settimio Rossi, Carlo Gesualdo, Michele Della Corte, Antonio Del Giudice, Andrea Rosolia, Maria Consiglia Trotta, Francesca Simonelli

PMC · DOI: 10.3389/fmed.2025.1605391 · 2025-06-16

## TL;DR

This pilot study tested a new lutein-based dye for eye surgery, showing it improves visibility and surgical outcomes for patients with a specific eye condition.

## Contribution

Introduces a new lutein-based dye for vitreoretinal surgery with demonstrated efficacy and safety.

## Key findings

- LB-VD effectively stained the vitreous body and posterior hyaloid, aiding surgical procedures.
- Patients showed significant improvements in visual acuity and retinal thickness over six months.
- Fixation stability improved in 95% of patients by six months post-surgery.

## Abstract

The use of vital dyes is essential for enhancing visualization of the vitreous and vitreoretinal interface during surgery. In this study, we evaluated the efficacy of a new lutein-based vital dye (LB-VD) for selective staining of the vitreous body and posterior hyaloid in patients undergoing 25 G vitrectomy for idiopathic epiretinal membrane (ERM).

A total of 18 patients who underwent ERM surgery assisted by LB-VD were retrospectively analyzed. The surgeon completed a postoperative satisfaction questionnaire to evaluate the vitreous staining. Data on best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP), and fixation stability were collected at baseline and at 4 and 6 months post-surgery.

LB-VD effectively stained the vitreous body and posterior hyaloid, facilitating key surgical maneuvers. Significant improvements were observed in BCVA and CRT at both 4 and 6 months post-surgery. Specifically, BCVA improved from 0.60 ± 0.29 LogMAR at baseline to 0.33 ± 0.26 LogMAR at 4 months (p = 0.004) and to 0.32 ± 0.25 LogMAR at 6 months (p = 0.003). CRT decreased significantly from 429 (375–499) μm at baseline to 335 (254–375) μm at 4 months (p = 0.03) and to 323 (240–356) μm at 6 months (p = 0.01). Fixation stability improved in approximately 95% of patients by 6 months. No significant changes in IOP were noted.

LB-VD provided clear visualization of the vitreous body and posterior hyaloid, thereby facilitating key vitreoretinal surgical tasks. These findings suggest that LB-VD is an effective and safe alternative to traditional dyes currently used in vitreoretinal surgery.

## Linked entities

- **Chemicals:** lutein (PubChem CID 181579)

## Full-text entities

- **Diseases:** ERM (MESH:D019773)
- **Chemicals:** Lutein (MESH:D014975)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12206756/full.md

---
Source: https://tomesphere.com/paper/PMC12206756